How should unknown amino acids be represented in a sequence listing?
The MPEP 2412.05(d) provides guidance on representing unknown amino acids in sequence listings: Use the symbol ‘X’ to represent unknown amino acids Provide further description in a feature table Use the feature key “UNSURE” and optionally the qualifier “note” The MPEP states, “Any “unknown” amino acid must be represented by the symbol “X” in the…
Read MoreHow are unknown nucleotides represented in a patent application?
According to MPEP 2412.05(b), unknown nucleotides in patent applications should be represented as follows: Use the symbol “n” to represent any unknown nucleotide in the sequence Further describe the unknown nucleotide in a feature table using the feature key “unsure” The symbol “n” is equivalent to only one residue The MPEP states, “Any “unknown” nucleotide…
Read MoreHow should modified residues be represented in a Sequence Listing XML?
Representing modified residues correctly in a Sequence Listing XML is crucial for accurately describing non-standard amino acids or nucleotides. According to MPEP 2413.01(g): “For the ‘note’ qualifier, where the variant residue is a modified residue not set forth in Table 2, the complete unabbreviated name of the modified residue must be provided as the qualifier…
Read MoreHow should modified nucleotides be represented in a sequence listing?
Modified nucleotides should be represented as follows: Represent the modified nucleotide as the corresponding unmodified nucleotide (a, c, g, or t) whenever possible. If it cannot be represented by an unmodified nucleotide, use the symbol “n”. Further describe the modification in the feature table using the feature key “modified_base” and the mandatory qualifier “mod_base”. Use…
Read MoreHow are modified amino acids represented in a sequence listing?
According to MPEP 2412.05(d), modified amino acids should be represented as follows: Represent as the corresponding unmodified amino acid when possible Use ‘X’ for modified amino acids that cannot be represented by other symbols Provide further description in a feature table The MPEP states, “WIPO Standard ST.26, paragraph 29, specifies that modified amino acids, including…
Read MoreWhat is a feature table in a Sequence Listing XML and why is it important?
A feature table in a Sequence Listing XML is a crucial component that provides information about various regions within a particular sequence. As stated in MPEP 2413.01(g): “A feature table is required for every sequence, except for any intentionally skipped sequence, in which case it must not be included. The feature table is contained in…
Read MoreWhat is the feature table in a “Sequence Listing XML”?
The feature table in a “Sequence Listing XML” contains information on the location and roles of various regions within a particular sequence. As stated in MPEP 2413.01(g): “A ‘feature table’ contains information on the location and roles of various regions within a particular sequence. A feature table is required for every sequence, except for any…
Read MoreHow are modified nucleotides described in a patent application?
Modified nucleotides in patent applications are described according to MPEP 2412.05(b) as follows: Represent modified nucleotides as the corresponding unmodified nucleotides (a, c, g, t) when possible Use the symbol “n” for modified nucleotides that cannot be represented by other symbols Further describe modified nucleotides in a feature table using the feature key “modified_base” Use…
Read MoreHow should regions of consecutive modified nucleotides be described in a patent application?
According to MPEP 2412.05(b), regions of consecutive modified nucleotides in patent applications should be described as follows: Describe the region in a feature table as required for a modified nucleotide Modified nucleotides in the region can be jointly described in a single INSDFeature element Provide the most restrictive unabbreviated chemical name or a list of…
Read More